ZYBERNO
Stock Report
Updated Aug 26, 2026

ENSYSCE BIOSCIENCES, INC. (ENSCW)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
ENSYSCE BIOSCIENCES, INC. (ENSCW) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-2,550.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-281.3%)
Return on Capital (Capital Efficiency):CRITICAL (-416.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ENSYSCE BIOSCIENCES, INC. (ENSCW) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$10.43K

Valuation Multiples (2)

P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$666.24K

Price Action & Momentum (1)

% of 52-Week High:2.7%
B. Profitability Assessment

Return Metrics (5)

ROA:-320.5%
Reinvestment Rate:-1.2%
Fundamental Growth Rate (g):5.1%

Margin Analysis (3)

Operating Margin Ttm:-281.3%
Net Margin Ttm:-280.5%
Ebitda Margin:-280.9%

TTM Performance (2)

Operating Margin Ttm:-281.3%
Net Margin Ttm:-280.5%

Yield Metrics (2)

Earnings Yield:-$315.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-33.3%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):38.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.70x
Quick Ratio:0.70x
Cash Ratio:0.17x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-640.30x
Times Interest Earned:-640.30

Capital Structure (4)

Working Capital:-1,221,896.00
Cash And Cash Equivalents:676,704.00
Long Term Debt:$35.00
Net Debt:-$676.67K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $4.50M
Linear Growth: 38.8%
📊 Click to view full ENSCW Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$12.66M

Bottom Line Performance (3)

-$12.62M
Income Before Tax:$0.00
Ebitda Ttm:-12,641,939.00

Operating Expenses (5)

Operating Expenses:17,162,292.00
R And D Expense:12,386,570.00
Sga Expense:4,775,722.00
Income Tax Expense:$0.00
Interest Expense:15,994.00

Expense Ratios (3)

R And D To Revenue Percentage:1,063.9%
Sga To Revenue Percentage:410.2%
Ebitda Margin:-280.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$2.96M
Current Assets:$2.85M
Ppe Net:111,063.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:4,068,106.00
Current Liabilities:4,068,106.00
Long Term Debt:$35.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$1.11M
Retained Earnings:-$145.85M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,977,629.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:8,743.00
C. Cash Flow Analysis

Operating Activities (2)

-$9.60M-$7.93M

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$63.95K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,000,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:19,599.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.52
-$2.52
Earnings Per Share Ttm:-$0.97

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.35
Operating Cash Flow Per Share:-$0.60

Book Value & Capital (2)

Book Value Per Share:-$0.09
Cash Per Share:0.05

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.14x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:160.38
Cash Conversion Cycle:-2,158.38
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-1.2%
Fundamental Growth Rate (g):5.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):38.8%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-5.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:ENSCW
Company Name:ENSYSCE BIOSCIENCES, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:13.04M
Shares Outstanding Basic:13.04M
Shares Outstanding Diluted:13.04M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 06:31:57 UTC
Data Timestamp:2026-08-26T06:31:57.899538
Scroll to Top